Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Small interfering RNAs (siRNA)02:30

Small interfering RNAs (siRNA)

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings.

Expert opinion on investigational drugs·2026
Same author

Safe and durable immune responses to a single dose DNA COVID-19 vaccine in previously vaccinated or SARS-CoV-2-infected adults: A phase 1 study.

Vaccine·2026
Same author

Effects of Serum Incubation on Lipid Nanoparticle PEG Shedding, mRNA Retention, and Membrane Interactions.

ACS applied materials & interfaces·2025
Same author

Corrigendum to "OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer" [Gynecol Oncol 2025 Jun 197 182-191].

Gynecologic oncology·2025
Same author

Intramuscular DNA vaccine provides protection in non-human primate and mouse models of SARS-CoV-2.

Frontiers in immunology·2025
Same author

OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.

Gynecologic oncology·2025
Same journal

Endogenous-metabolite-inspired polyamine-oleic acid lipids for safe mRNA delivery and PCSK9 gene editing.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Tunable rigid spikes on virus-like porous silica enable mechanistically controlled nanovaccine platforms.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Metabolic regulation-driven nanoparticles for tumor vulnerabilization and enhanced photodynamic therapy.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

New approach methodologies (NAMs) for preclinical and translational evaluation of mRNA-lipid nanoparticle (LNP) therapeutics.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

A cation-free platform based on azocalixarene poly(disulfide)s for direct cytosolic protein delivery.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Harnessing plant-derived extracellular vesicles for oral delivery: A dual role as natural therapeutics and engineered drug carriers.

Journal of controlled release : official journal of the Controlled Release Society·2026
See all related articles

Related Experiment Video

Updated: May 27, 2026

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
15:55

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Published on: June 21, 2013

Versatile cationic lipids for siRNA delivery.

Jeff Sparks1, Gregory Slobodkin, Majed Matar

  • 1EGEN Inc., 601 Genome Way, Huntsville AL 35806, USA. jsparks@egeninc.com

Journal of Controlled Release : Official Journal of the Controlled Release Society
|November 22, 2011
PubMed
Summary
This summary is machine-generated.

Researchers developed novel cationic lipopolyamines for safe and effective RNA interference (RNAi) therapy delivery. These nanoparticles successfully reduced target gene expression in lung tissue with minimal toxicity, showing promise for pulmonary disease treatments.

More Related Videos

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
08:29

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Published on: February 1, 2019

Related Experiment Videos

Last Updated: May 27, 2026

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
15:55

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Published on: June 21, 2013

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
08:29

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Published on: February 1, 2019

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Drug Delivery Systems

Background:

  • RNA interference (RNAi) pathway holds therapeutic potential for various diseases.
  • Current clinical development is hindered by the absence of safe and efficient delivery systems for RNAi-based drugs.

Purpose of the Study:

  • To develop versatile cationic lipopolyamines for effective small interfering RNA (siRNA) delivery.
  • To evaluate the in vivo efficacy and safety of modified lipopolyamines for pulmonary RNAi therapeutics.

Main Methods:

  • Synthesized structurally versatile cationic lipopolyamines for siRNA delivery.
  • Modified a core lipid (Staramine) with methoxypolyethylene glycols (mPEGs) for in vivo applications.
  • Administered PEGylated Staramine nanoparticles with siRNA targeting caveolin-1 (Cav-1) transcript in vivo.

Main Results:

  • Achieved high levels of target transcript knockdown in vitro across various cell types.
  • Demonstrated significant reduction (up to 60%) of Cav-1 transcript in lung tissue 48 hours post-administration.
  • Observed reduced toxicity associated with intravenous administration of mPEG-modified nanoparticles.

Conclusions:

  • Developed lipopolyamines show potential as effective siRNA delivery vehicles.
  • PEGylated Staramine nanoparticles are promising for RNAi therapeutics targeting pulmonary diseases.
  • The system allows for tunable gene knockdown and reduced toxicity, facilitating clinical translation.